肝硬化患者营养评估及营养支持治疗*

doi:10.3969/j.issn.1672-5069.2014.05.004

Abstract

Cao Haixia, Fan Jiangao. Nutritional assessment and support treatment of patients with liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(5): 459-462.

[1] Kalaitzakis E,Simrén M,OIsson R,et a1. Gastrointestinal symptoms in patients with liver cirrhosis:associations with nutritional status and health-related quailty of life. Scand J Gastroenterol,2006,41（12）:1464-1472.
[2] Cheung K,Lee SS,Raman M. Prevalence and mechanisms of malnutrition in patients with advanced liver disease,and nutrition management strategies. Clin Gastroenterol Hepatol,2012,10（2）:117-125.
[3] Cabré E,Gassull MA. Nutrition in liver disease. Curr Opin Clin Nutr Metab Care,2005,8（5）:545-551.
[4] Campillo B,Richardet JP,Bories PN. Enteral nutrition in severely malnourished and anorectic cirrhotic patients in clinical practice. Gastroenterol Clin Biol,2005,29（6-7）:645-651.
[5] Figueiredo FA,Dickson ER,Pasha TM,et al. Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end-stage liver disease. Liver Transplant,2000,6（5）:575-581.
[6] Peres WA,Lento DF,Baluz K,et al. Phase angle as a nutritional evaluation tool in all stages of chronic liver disease. Nutr Hosp,2012,27（6）:2072-2078.
[7] Detsky AS,McLaughlin JR,Baker JP,et a1. What is subjective global assessment of nutritional status. J Parenter Enteral Nutr, 1987,11（1）:8-13.
[8] Plauth M,Cabré E,Riggio O,et a1. ESPEN guidelines on enteral nutrition：liver disease. Clin Nutr,2006,25（2）:285-294.
[9] Morgan MY,Madden AM,Soulsby CT,et a1. Derivation and validation of a new global method for assessing nutritional status in patients with cirrhosis. Hepatology,2006,44（4）:823-835.
[10] Kondrup J,Rasmussen HH,Hamberg O,et a1. Nutritional risk screening（NRS2002）:a new method based on an analysis of controlled clinical trials. Clin Nutr,2003,22（3）:321-336.
[11] Poulia KA,Yannakoulia M,Karageorgou D,et al. Evaluation of the efficacy of six nutritional screening tools to predict malnutrition in the elderly. Clin Nutr,2012,31（3）:378-385.
[12] Plauth M,Cabré E,Campillo B,et al. ESPEN Guidelines on parenteral nutrition:hepatology. Clin Nutr,2009,28（4）:436-444.
[13] Ney M,Vandermeer B,van Zanten SJ,et al. Meta-analysis: oral or enteral nutritional supplementation in cirrhosis. Aliment Pharmacol Ther,2013,37（7）:672-679.
[14] Koretz RL,Avenell A,Lipman TO. Nutritional support for liver disease. Cochrane Database Syst Rev,2012,5:CD008344.
[15] Van Gossum A,Cabre E,Hebuterne X,et al. ESPEN Guidelines on parenteral nutrition:gastroenterology. Clin Nutr,2009,28（4）:415-427.

Nutritional assessment and support treatment of patients with liver cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[3]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[4]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[5]	Zhang Rui, Wang Jian, Chen Shiyao.. Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 930-933.
[6]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[7]	. [J]. Journal of Practical Hepatology, 2019, 22(5): 624-635.
[8]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[9]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[10]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.
[11]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[12]	Zhao Fangfang, Zhai Yongzhen, Feng Guohe. Efficacy and safety of autologous peripheral blood stem cell transplantation in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 700-703.
[13]	Chen Shan, Zhuang Huashuai, Xing Yixi, et al. Preventive application of meropenem in patients with liver cirrhosis complicated by upper gastrointestinal bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 704-707.
[14]	Xu Qilin, Hao Shaohuan, Ran Bo. Risk factors of portal vein thrombosis after splenectomy in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2019, 22(5): 708-711.
[15]	Jin Lianghong, Li Xingjie, Guan Hongbo, et al. Clinical value of dual-energy CT iodine quantification combined with dynamic contrast-enhanced MRI in evaluating hepatic hemodynamics and liver functions in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 712-715.